Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

US10745387B2 · kind B2 · utility

Assignee

• Eisai R&D Management Co., Ltd. · JP

Inventors

• Gregg F. Keaney · Lexington, US
• John Wang · Andover, US
• Baudouin Gérard · Belmont, US
• Kenzo Arai · Ibaraki, JP
• Xiang LIU · Winchester, US
• Guo Zhu Zheng · Lexington, US
• Kazunobu Kira · Tsukuba, JP
• Parcharee Tivitmahaisoon · San Francisco, US
• Sudeep Prajapati · Somerville, US
• Nicholas C. Gearhart · Durango, US
• Yoshihiko Kotake · Ibaraki, JP
• Satoshi Nagao · Tsukuba, JP
• Regina Mikie Kanada Sonobe · Ibaraki, JP
• Masayuki Miyano · Tsukubamirai, JP
• Norio Murai
• Silvia Buonamici · Boston, US
• Lihua Yu · Acton, US
• Eunice Sun Park · Arlington, US
• Betty Chan · Harvard, US
• Peter Smith · Arlington, US
• Michael Thomas · Weisenheim am Berg, DE
• Ermira Pazolli · Wayland, US
• Kian Huat Lim · Burlington, US
• Atsushi Endo · Boston, US
• Arani Chanda · Malden, US

Key dates

• Filing date: Nov 17, 2016
• Grant date: Aug 18, 2020
• Expiry date: May 13, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.